Medinice S.A (ICE) - Net Assets
Based on the latest financial reports, Medinice S.A (ICE) has net assets worth zł88.12 Million PLN (≈ $24.25 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł92.73 Million ≈ $25.52 Million USD) and total liabilities (zł4.62 Million ≈ $1.27 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ICE goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł88.12 Million |
| % of Total Assets | 95.02% |
| Annual Growth Rate | 102.8% |
| 5-Year Change | 117.15% |
| 10-Year Change | N/A |
| Growth Volatility | 626.4 |
Medinice S.A - Net Assets Trend (2016–2025)
This chart illustrates how Medinice S.A's net assets have evolved over time, based on quarterly financial data. See Medinice S.A (ICE) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Medinice S.A (2016–2025)
The table below shows the annual net assets of Medinice S.A from 2016 to 2025. For live valuation and market cap data, see ICE market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | zł88.12 Million ≈ $24.25 Million |
+8.77% |
| 2024-12-31 | zł81.01 Million ≈ $22.30 Million |
+144.26% |
| 2023-12-31 | zł33.17 Million ≈ $9.13 Million |
-10.67% |
| 2022-12-31 | zł37.13 Million ≈ $10.22 Million |
-8.51% |
| 2021-12-31 | zł40.58 Million ≈ $11.17 Million |
+139.04% |
| 2020-12-31 | zł16.98 Million ≈ $4.67 Million |
+106.38% |
| 2019-12-31 | zł8.23 Million ≈ $2.26 Million |
+182.18% |
| 2018-12-31 | zł2.92 Million ≈ $802.27K |
-10.71% |
| 2017-12-31 | zł3.26 Million ≈ $898.55K |
+2048.69% |
| 2016-12-31 | zł151.95K ≈ $41.82K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medinice S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1012289132.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł9.72 Million | 11.03% |
| Other Components | zł78.40 Million | 88.97% |
| Total Equity | zł88.12 Million | 100.00% |
Medinice S.A Competitors by Market Cap
The table below lists competitors of Medinice S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coherus BioSciences Inc
NASDAQ:CHRS
|
$206.85 Million |
|
Chicago Atlantic BDC, Inc.
NASDAQ:LIEN
|
$206.98 Million |
|
Appen Ltd
AU:APX
|
$207.10 Million |
|
Lotte Data Communication Company
KO:286940
|
$207.11 Million |
|
Smart Sand Inc
NASDAQ:SND
|
$206.76 Million |
|
TERACT EO 1
F:6O8
|
$206.71 Million |
|
Tantalus Systems Holding Inc
TO:GRID
|
$206.63 Million |
|
Aekyung Industrial Co Ltd
KO:018250
|
$206.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medinice S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 81,010,000 to 88,117,000, a change of 7,107,000 (8.8%).
- Net loss of 6,723,000 reduced equity.
- New share issuances of 12,031,000 increased equity.
- Other comprehensive income decreased equity by 6,900,000.
- Other factors increased equity by 8,699,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-6.72 Million | -7.63% |
| Share Issuances | zł12.03 Million | +13.65% |
| Other Comprehensive Income | zł-6.90 Million | -7.83% |
| Other Changes | zł8.70 Million | +9.87% |
| Total Change | zł- | 8.77% |
Book Value vs Market Value Analysis
This analysis compares Medinice S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1776.62x to 8.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | zł0.05 | zł80.90 | x |
| 2017-12-31 | zł0.98 | zł80.90 | x |
| 2018-12-31 | zł0.87 | zł80.90 | x |
| 2019-12-31 | zł1.89 | zł80.90 | x |
| 2020-12-31 | zł3.17 | zł80.90 | x |
| 2021-12-31 | zł7.04 | zł80.90 | x |
| 2022-12-31 | zł5.78 | zł80.90 | x |
| 2023-12-31 | zł5.19 | zł80.90 | x |
| 2024-12-31 | zł12.12 | zł80.90 | x |
| 2025-12-31 | zł9.67 | zł80.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medinice S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-7.63%) is above the historical average (-32.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -211.00% | -173.54% | 0.13x | 9.58x | zł-335.80K |
| 2017 | -15.53% | -208.69% | 0.05x | 1.50x | zł-833.67K |
| 2018 | -56.71% | -148935.44% | 0.00x | 2.59x | zł-1.94 Million |
| 2019 | -27.31% | -1366.43% | 0.01x | 1.42x | zł-3.07 Million |
| 2020 | -17.79% | -812.10% | 0.02x | 1.23x | zł-4.72 Million |
| 2021 | -7.10% | -1001.04% | 0.01x | 1.21x | zł-6.94 Million |
| 2022 | -13.27% | -2002.03% | 0.01x | 1.13x | zł-8.64 Million |
| 2023 | -15.29% | -2254.22% | 0.01x | 1.13x | zł-8.39 Million |
| 2024 | 46.39% | 19987.77% | 0.00x | 1.07x | zł29.48 Million |
| 2025 | -7.63% | 0.00% | 0.00x | 1.05x | zł-15.53 Million |
Industry Comparison
This section compares Medinice S.A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $27,241,026
- Average return on equity (ROE) among peers: -201.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medinice S.A (ICE) | zł88.12 Million | -211.00% | 0.05x | $206.77 Million |
| Adiuvo Investment SA (ADV) | $-44.73 Million | 0.00% | 0.00x | $1.81 Million |
| Braster S.A. (BRA) | $29.02 Million | -68.18% | 0.88x | $4.69 Million |
| Genomtec S.A. (GMT) | $738.00K | -964.09% | 4.71x | $21.68 Million |
| Medicalg (MDG) | $80.93 Million | 13.44% | 0.03x | $74.23 Million |
| Synektik S.A. (SNT) | $70.25 Million | 13.00% | 0.78x | $748.80 Million |
About Medinice S.A
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technol… Read more